Denosumab

Form: Injection

Strength: 60 mg/mL, 120 mg/1.7 mL

Reference Brands: Prolia, Xgeva

Category: Osteoporosis

Denosumab is a leading RANKL-inhibiting monoclonal antibody used in the treatment of osteoporosis, cancer-related bone loss, and bone metastases. Available as a 60 mg/mL prefilled syringe (Prolia®) for biannual dosing and 120 mg/1.7 mL (Xgeva®) for monthly administration, Denosumab offers effective and long-acting bone protection. Trusted globally under Amgen's Prolia and Xgeva brands, it is approved across the US and EU. Denosumab is manufactured in GMP-certified facilities and is available for B2B pharmaceutical distribution, including hospitals and oncology clinics. Contact us for bulk export, COAs, and regulatory documentation.